Experimental Eye Research, Journal Year: 2024, Volume and Issue: 248, P. 110126 - 110126
Published: Oct. 16, 2024
Language: Английский
Biomedicine & Pharmacotherapy, Journal Year: 2023, Volume and Issue: 168, P. 115633 - 115633
Published: Oct. 6, 2023
Glaucoma is the world's leading irreversible blinding eye disease. Lowering intraocular pressure currently only effective clinical treatment. However, there a lack of long-acting IOP-lowering drugs, and some patients still experience retinal ganglion cell loss even with good control. Currently, no method for neuroprotection regeneration in practice glaucoma. In recent years, epigenetics has been widely researched reported its role glaucoma's regeneration. This article reviews changes histone modifications, DNA methylation, non-coding RNA, m6A methylation glaucoma, aiming to provide new perspectives glaucoma management, protection cells, axon by understanding epigenetic alterations.
Language: Английский
Citations
11
Journal of Materials Chemistry A, Journal Year: 2024, Volume and Issue: 12(27), P. 16457 - 16465
Published: Jan. 1, 2024
An eye-wearable Ti 3 C 2 T x MXene-based micro-supercapacitor was fabricated on a soft hemispherical substrate, which can be used as an efficient power unit for intraocular pressure applications.
Language: Английский
Citations
4
Advanced Science, Journal Year: 2024, Volume and Issue: 11(41)
Published: Sept. 4, 2024
Abstract Glaucoma is an irreversible blinding eye disease characterized by retinal ganglion cell (RGC) death.Previous studies have demonstrated that protecting mitochondria and activating the CaMKII/CREB signaling pathway can effectively protect RGC axon. However, currently treatments are often unsatisfactory, pathogenesis of glaucoma requires further elucidation. In this study, a ROS‐responsive dual drug conjugate (OLN monomer) first designed simultaneously bonds nicotinamide oleic acid. The self‐assembled into nanoparticles (uhOLN‐NPs) through aggregation multiple micelles possesses ROS scavenging capability. Then, polymer with hypoxic response function designed, which encapsulates uhOLN‐NPs to form responses (HOLN‐NPs). Under hypoxia in RGCs, azo bond HOLN‐NPs breaks releases uhOLN‐NPs. Meanwhile, under high conditions, thioketone broke, leading dissociation nano‐prodrug. released acid co‐scavenge activate pathway, RGCs. exhibit significantly superior protective effect on R28 cells glutamate models glaucoma. accumulation RGCs lead significant inhibition apoptosis axonal damage vivo. Notably, provide new therapeutic approach for patients neurodegenerative disease.
Language: Английский
Citations
4
Pharmaceuticals, Journal Year: 2024, Volume and Issue: 17(10), P. 1261 - 1261
Published: Sept. 25, 2024
Glaucoma is a major global health concern and the leading cause of irreversible blindness worldwide, characterized by progressive degeneration retinal ganglion cells (RGCs) their axons. This review focuses on need for neuroprotective strategies in glaucoma management, addressing limitations current treatments that primarily target intraocular pressure (IOP) reduction. Despite effective IOP many patients continue to experience RGC degeneration, blindness. provides an overview both pharmacological interventions emerging technologies aimed at directly protecting RGCs optic nerve, independent Pharmacological agents such as brimonidine, neurotrophic factors, memantine, Ginkgo biloba extract, citicoline, nicotinamide, insulin, resveratrol show promise preclinical early clinical studies properties. Emerging technologies, including stem cell therapy, gene mitochondrial-targeted therapies, nanotechnologies, offer innovative approaches neuroprotection regeneration damaged RGCs. While these hold significant potential, further research trials are necessary confirm efficacy establish role practice. highlights multifaceted nature glaucoma, aiming guide future practice toward more management glaucoma-induced neurodegeneration.
Language: Английский
Citations
4
Journal of Ocular Pharmacology and Therapeutics, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 8, 2025
Vitamin E is renowned for its potent antioxidant properties, crucial shielding cells against oxidative stress and damage. Deficiency in this vitamin can lead to various health issues, including neurodegenerative diseases, due pivotal role preserving cell membrane integrity combating cellular While importance overall health, neurodegeneration, acknowledged, the specific correlation between deficiency distinct ocular disorders need be further explored. This review delves into molecular mechanisms of disorders; diabetic retinopathy, age-related macular degeneration, glaucoma, cataracts, emphasising therapeutic implications drawn from existing evidence. Relationship widely researched on, with primary protective attributed anti-inflammatory properties. However, studies on supplementation among human subjects present mixed results, suggesting complexities variability depending factors such as disorder, disease stage, genetic differences, form utilized. In conclusion, while holds promise mitigating neurodegeneration through supplementation's efficacy remains nuanced context dependent. More research works are essential elucidate precise potential disorders.
Language: Английский
Citations
0
Biointerphases, Journal Year: 2025, Volume and Issue: 20(1)
Published: Jan. 1, 2025
The special structure of eyes and the existence various physiological barriers make ocular drug delivery one most difficult problems in pharmaceutical field. Considering patient compliance, local administration remains preferred method anterior part eyes. However, suffers from poor bioavailability, need for frequent administration, systemic toxicity. Administration posterior eye is more difficult, intravitreal injection often used. But faces compliance likely side effects after multiple injections. development nanocarrier technology provides an effective way to solve these problems. Among them, liposomes, as widely used carrier clinical application, have characteristics amphiphilic nanostructure, easy surface modification, extended release time, good biocompatibility, etc. liposomes are expected overcome obstacles effectively deliver drugs target site improve bioavailability. This review summarized controllable properties well application research progress diseases. In addition, we routes contained eyes, prospects treatment
Language: Английский
Citations
0
Cell and Tissue Biology, Journal Year: 2025, Volume and Issue: 19(1), P. 9 - 18
Published: Jan. 20, 2025
Language: Английский
Citations
0
Clinical and Experimental Optometry, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 7
Published: Feb. 12, 2025
Glaucoma is a multifactorial neurodegenerative disorder characterised by the progressive loss of retinal ganglion cells, ultimately leading to irreversible blindness worldwide. Recent research highlights metabolic dysregulation as crucial factor in pathophysiology glaucoma. This review examines intricate relationship between processes and glaucoma, with focus on key mechanisms such mitochondrial dysfunction, lipid metabolism, glucose roles specific metabolites. Mitochondrial dysfunction commonly observed impaired energy production that compromises cellular viability. Alterations including changes fatty acid profiles peroxidation, contribute injury apoptosis cells. Moreover, disturbances reduced glycolytic activity, affect availability neurotrophic support are vital for cells survival. The also explores metabolites, lactate glutamate, context health, how their may exacerbate glaucomatous damage. Additionally, interplay elevated intraocular pressure analysed, particularly regard its impact ocular blood flow health. Understanding these essential identifying potential therapeutic strategies. By deepening our understanding foundations new avenues effective treatments arise, addressing nature this complex disease improving patient outcomes.
Language: Английский
Citations
0
Advanced Healthcare Materials, Journal Year: 2025, Volume and Issue: unknown
Published: March 24, 2025
Abstract Glaucoma, a leading cause of irreversible blindness worldwide, is characterized by optic nerve damage often associated with elevated intraocular pressure (IOP). Although gas therapies hold promise for glaucoma treatment, the limitations single‐gas strategies constrain their therapeutic efficacy. Here, photoresponsive dual‐gas nanomedicine developed targeted therapy. The nanomedicine, PdH‐D‐S, engineered synthesizing mesoporous palladium hydride (meso‐PdH) efficient hydrogen (H₂) storage capacity and abundant pore channels, followed surface modification DSPE‐mPEG loading sodium nitroprusside (SNP) as nitric oxide (NO) donor. PdH‐D‐S penetrates cornea to reach IOP‐regulating tissues, including trabecular meshwork Schlemm's canal. Upon 808 nm laser excitation, releases H₂ NO in controlled manner. activates AKT/p‐AKT/eNOS/sGC signaling pathway, while binds soluble guanylate cyclase (sGC), converting guanosine triphosphate (GTP) cyclic monophosphate (cGMP), relaxing cells enhancing aqueous humor outflow. This system demonstrates high efficacy lowering IOP offers mechanistic advancement treatment through synergistic
Language: Английский
Citations
0
Colloids and Surfaces B Biointerfaces, Journal Year: 2025, Volume and Issue: unknown, P. 114659 - 114659
Published: April 1, 2025
Language: Английский
Citations
0